Antipsychotic  	Antipsychotic  	 JJ	B-NP
long-acting  	long-acting  	 JJ	I-NP
injections 	injections 	 NNS	I-NP
:  	:  	 :	O
prescribing  	prescribing  	 JJ	O
practice  	practice  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
UK  	UK  	 NNP	B-NP
Data  	Data  	 NNP	I-NP
from  	from  	 IN	O
the  	the  	 DT	O
USA 	USA 	 NNP	B-NP
,  	,  	 ,	O
Australia  	Australia  	 NNP	B-NP
and  	and  	 CC	O
Europe  	Europe  	 NNP	O
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
schizophrenia  	schizophrenia  	 NN	O
prescribed  	prescribed  	 VBN	O
an  	an  	 DT	O
antipsychotic  	antipsychotic  	 JJ	B-NP
long-acting  	long-acting  	 JJ	I-NP
injection  	injection  	 NN	I-NP
( 	( 	 -LRB-	O
LAI 	LAI 	 NNP	B-NP
)  	)  	 -RRB-	O
varies  	varies  	 VBZ	O
from  	from  	 IN	O
around  	around  	 IN	O
a  	a  	 DT	O
quarter  	quarter  	 NN	O
to  	to  	 TO	O
a  	a  	 DT	O
third 	third 	 JJ	O
.  	.  	 .	O
Use  	Use  	 NN	O
of  	of  	 IN	O
LAIs  	LAIs  	 NNP	B-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
male  	male  	 JJ	O
gender  	gender  	 NN	B-NP
and  	and  	 CC	O
younger  	younger  	 JJR	O
age 	age 	 NN	O
.  	.  	 .	O
To  	To  	 TO	O
characterise  	characterise  	 VB	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
LAIs  	LAIs  	 JJ	B-NP
in  	in  	 IN	O
people  	people  	 NNS	O
with  	with  	 IN	O
schizophrenia  	schizophrenia  	 NN	O
in  	in  	 IN	O
three  	three  	 CD	O
clinical  	clinical  	 JJ	B-NP
settings  	settings  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
UK 	UK 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
study  	study  	 NN	O
used  	used  	 VBN	O
audit  	audit  	 NN	B-NP
data  	data  	 NNS	I-NP
from  	from  	 IN	O
quality  	quality  	 NN	B-NP
improvement  	improvement  	 NN	I-NP
programmes  	programmes  	 VBZ	O
conducted  	conducted  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
Prescribing  	Prescribing  	 NNP	B-NP
Observatory  	Observatory  	 NNP	I-NP
for  	for  	 IN	I-NP
Mental  	Mental  	 NNP	I-NP
Health 	Health 	 NNP	I-NP
.  	.  	 .	O
Long-acting  	Long-acting  	 JJ	B-NP
injections  	injections  	 NNS	I-NP
were  	were  	 VBD	O
found  	found  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
prescribed  	prescribed  	 VBN	O
for  	for  	 IN	O
between  	between  	 IN	O
a  	a  	 DT	O
quarter  	quarter  	 NN	O
and  	and  	 CC	O
a  	a  	 DT	O
third  	third  	 JJ	O
of  	of  	 IN	O
patients 	patients 	 NNS	O
,  	,  	 ,	O
depending  	depending  	 VBG	O
on  	on  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
setting 	setting 	 NN	I-NP
.  	.  	 .	O
Flupentixol 	Flupentixol 	 NNP	B-NP
,  	,  	 ,	O
risperidone  	risperidone  	 NN	B-NP
and  	and  	 CC	O
zuclopenthixol  	zuclopenthixol  	 NNS	B-NP
were  	were  	 VBD	O
most  	most  	 RBS	O
commonly  	commonly  	 RB	O
prescribed  	prescribed  	 VBN	O
and  	and  	 CC	O
were  	were  	 VBD	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
an  	an  	 DT	O
oral  	oral  	 JJ	B-NP
antipsychotic  	antipsychotic  	 NN	I-NP
in  	in  	 IN	O
half  	half  	 NN	O
of  	of  	 IN	O
cases 	cases 	 NNS	O
,  	,  	 ,	O
frequently  	frequently  	 RB	O
constituting  	constituting  	 JJ	O
high-dose  	high-dose  	 JJ	B-NP
prescribing 	prescribing 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
LAIs  	LAIs  	 NNP	B-NP
was  	was  	 VBD	O
not  	not  	 RB	O
consistently  	consistently  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
age 	age 	 NN	O
,  	,  	 ,	O
gender  	gender  	 NN	B-NP
or  	or  	 CC	O
ethnicity 	ethnicity 	 NN	B-NP
.  	.  	 .	O
Antipsychotic  	Antipsychotic  	 JJ	B-NP
LAIs  	LAIs  	 NNS	I-NP
are  	are  	 VBP	O
commonly  	commonly  	 RB	O
prescribed 	prescribed 	 VBN	O
.  	.  	 .	O
We  	We  	 PRP	O
did  	did  	 VBD	O
not  	not  	 RB	O
replicate  	replicate  	 VB	O
previous  	previous  	 JJ	O
findings  	findings  	 NNS	O
with  	with  	 IN	O
respect  	respect  	 NN	O
to  	to  	 TO	O
demographic  	demographic  	 JJ	B-NP
variables  	variables  	 NNS	I-NP
associated  	associated  	 VBN	O
with  	with  	 IN	O
their  	their  	 PRP$	O
use 	use 	 NN	O
.  	.  	 .	O
